MicroRNA Biomarkers in Pancreatic Cancer Diagnosis and Prognosis

Pancreatic cancer remains one of the most lethal malignancies worldwide, often diagnosed at an advanced stage due to nonspecific symptoms and the lack of sensitive early detection tools. MicroRNAs (miRNAs)—small non-coding RNA molecules that post-transcriptionally regulate gene expression—have emerged as promising biomarkers for both diagnosis and prognosis. Aberrant miRNA expression profiles can reflect tumour presence, stage and biological behaviour, offering a minimally invasive window into disease status through blood, saliva or other body fluids. Panels of circulating miRNAs have demonstrated improved sensitivity and specificity compared with conventional markers such as CA19-9, enabling discrimination between pancreatic cancer, chronic pancreatitis and healthy controls. Beyond diagnosis, specific miRNAs correlate with tumour aggressiveness, metastatic potential and patient survival, guiding prognostic stratification and therapeutic decision-making. Technological advances in sequencing, machine-learning algorithms and standardised assay workflows have accelerated the translation of miRNA signatures into clinical research, while investigations into the underlying biology of dysregulated miRNAs continue to unveil novel targets for intervention. Collectively, the current landscape underscores the global significance of miRNA biomarkers in transforming the early detection and management of pancreatic cancer.

Research from Nature Portfolio

Studies have elucidated the dualistic roles of TGF-β-induced miRNAs in pancreatic ductal adenocarcinoma. One foundational work characterised the transcriptional induction of MIR100HG-derived miR-100 and miR-125b alongside the blockade of tumour-suppressive let-7a, demonstrating that miR-100 and miR-125b co-ordinately repress p53 and cell-junction pathways, thus driving epithelial-to-mesenchymal transition and stemness. This mechanistic insight has paved the way for targeting miRNA networks in TGF-β-driven tumour progression. Another seminal contribution identified a robust circulating pattern of seven miRNAs, highlighting miR-21-5p as markedly elevated in the serum of pancreatic cancer patients. The resulting miRNA classifier achieved high diagnostic accuracy, sensitivity and specificity, validating circulating miR-21-5p as a non-invasive adjunct to imaging and conventional markers and underscoring its prognostic relevance in stratifying patient risk.

MicroRNA Biomarkers in Pancreatic Cancer Diagnosis and Prognosis publication trend

The graph below shows the total number of articles in microrna biomarkers in pancreatic cancer diagnosis and prognosis across all publications each year (not limited to Nature Index journals).

Technical terms

microRNA (miRNA): Small non-coding RNA molecules (~22 nucleotides) that regulate gene expression by binding target mRNAs.

Biomarker: A measurable indicator of a biological state, used for disease detection, prognosis or monitoring therapeutic response.

Liquid biopsy: A minimally invasive test analysing circulating components (e.g. miRNAs, DNA) in body fluids to diagnose or monitor disease.

Epithelial-to-mesenchymal transition (EMT): A cellular process in which epithelial cells acquire migratory and invasive properties, often driven by miRNA networks.

Tumour microenvironment (TME): The complex milieu surrounding cancer cells, including extracellular matrix, stromal cells and immune infiltrates, influenced by miRNAs.

References

1. TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nature Communications (2018).
2. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validation. Scientific Reports (2017).
3. Circulating microRNAs as Potential Biomarkers in Pancreatic Cancer—Advances and Challenges. International Journal of Molecular Sciences (2023).
4. Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinoma. Precision Clinical Medicine (2023).
5. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer. British Journal of Cancer (2023).